Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine: A case report and brief review

Immune-Mediated Necrotizing Myopathy (IMNM) after vaccination has been reported previously, however it is rare after COVID-19 vaccination. We report the first case of IMNM two weeks after vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine. There was a probable temporal relationship between...

Descripción completa

Detalles Bibliográficos
Autores principales: Ansari, B., Najafi, M.A., Kheradmand, M., Najafi, F., Najafi, M.R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889262/
https://www.ncbi.nlm.nih.gov/pubmed/36754672
http://dx.doi.org/10.1016/j.neurol.2022.11.009
_version_ 1784880693959983104
author Ansari, B.
Najafi, M.A.
Kheradmand, M.
Najafi, F.
Najafi, M.R.
author_facet Ansari, B.
Najafi, M.A.
Kheradmand, M.
Najafi, F.
Najafi, M.R.
author_sort Ansari, B.
collection PubMed
description Immune-Mediated Necrotizing Myopathy (IMNM) after vaccination has been reported previously, however it is rare after COVID-19 vaccination. We report the first case of IMNM two weeks after vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine. There was a probable temporal relationship between the COVID-19 vaccination and the development of IMNM due to lack of known causative factors for IMNM. This may have been due to 1) autoimmunity directly caused by the vaccine, 2) exacerbation of autoimmunity triggered by the vaccine or 3) autoimmune syndrome triggered by the vaccine adjutants. Further studies are needed to assess the underlying mechanisms.
format Online
Article
Text
id pubmed-9889262
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-98892622023-02-01 Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine: A case report and brief review Ansari, B. Najafi, M.A. Kheradmand, M. Najafi, F. Najafi, M.R. Rev Neurol (Paris) Brief Report Immune-Mediated Necrotizing Myopathy (IMNM) after vaccination has been reported previously, however it is rare after COVID-19 vaccination. We report the first case of IMNM two weeks after vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine. There was a probable temporal relationship between the COVID-19 vaccination and the development of IMNM due to lack of known causative factors for IMNM. This may have been due to 1) autoimmunity directly caused by the vaccine, 2) exacerbation of autoimmunity triggered by the vaccine or 3) autoimmune syndrome triggered by the vaccine adjutants. Further studies are needed to assess the underlying mechanisms. Elsevier Masson SAS. 2023-06 2023-02-01 /pmc/articles/PMC9889262/ /pubmed/36754672 http://dx.doi.org/10.1016/j.neurol.2022.11.009 Text en © 2023 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Brief Report
Ansari, B.
Najafi, M.A.
Kheradmand, M.
Najafi, F.
Najafi, M.R.
Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine: A case report and brief review
title Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine: A case report and brief review
title_full Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine: A case report and brief review
title_fullStr Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine: A case report and brief review
title_full_unstemmed Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine: A case report and brief review
title_short Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine: A case report and brief review
title_sort immune-mediated necrotizing myopathy following vaccination with the astrazeneca (azd1222) covid-19 vaccine: a case report and brief review
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889262/
https://www.ncbi.nlm.nih.gov/pubmed/36754672
http://dx.doi.org/10.1016/j.neurol.2022.11.009
work_keys_str_mv AT ansarib immunemediatednecrotizingmyopathyfollowingvaccinationwiththeastrazenecaazd1222covid19vaccineacasereportandbriefreview
AT najafima immunemediatednecrotizingmyopathyfollowingvaccinationwiththeastrazenecaazd1222covid19vaccineacasereportandbriefreview
AT kheradmandm immunemediatednecrotizingmyopathyfollowingvaccinationwiththeastrazenecaazd1222covid19vaccineacasereportandbriefreview
AT najafif immunemediatednecrotizingmyopathyfollowingvaccinationwiththeastrazenecaazd1222covid19vaccineacasereportandbriefreview
AT najafimr immunemediatednecrotizingmyopathyfollowingvaccinationwiththeastrazenecaazd1222covid19vaccineacasereportandbriefreview

Ejemplares similares